Among the list of the top 10 most promising COVID-19 therapeutics just published by the European Commission is a monoclonal antibody that was last month rejected by the US Food and Drug Administration for an emergency use authorization – Humanigen, Inc.’s lenzilumab for preventing and treating the “cytokine storm” often seen in patients newly hospitalized with COVID-19.
Other products added to the commission’s expanded portfolio include AstraZeneca PLC’s Evusheld (tixagevimab + cilgavimab), Atea Pharmaceuticals, Inc./Roche Holding AG’s oral RNA viral polymerase inhibitor, AT-527, and Pfizer Inc
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?